08:00 , Feb 8, 2016 |  BC Week In Review  |  Clinical News

Ovax: Phase I/II data

A double-blind, U.S. Phase I/II trial in 34 patients with relapsed stage III or IV ovarian cancer who have undergone debulking followed by intraperitoneal chemotherapy showed that once-weekly 0.5, 2.5 and 5 million ovarian cancer...
08:00 , Mar 1, 2010 |  BC Week In Review  |  Company News

TopoTarget management update

TopoTarget A/S (CSE:TOPO), Copenhagen, Denmark   Business: Cancer   Hired: Francois Martelet as CEO, formerly president and CEO of Avax Technologies Inc. ; he replaces Peter Jensen, who will remain a consultant for six months...
01:10 , Feb 24, 2010 |  BC Extra  |  Company News

TopoTarget names Martelet CEO

Cancer company TopoTarget A/S (CSE:TOPO) hired Francois Martelet as CEO. He replaces Peter Jensen, who will remain a consultant for six months. Martelet was previously president and CEO of Avax Technologies Inc. (Pink:AVXT), also a...
08:00 , Dec 21, 2009 |  BC Week In Review  |  Financial News

Avax completes private placement of convertible notes and warrants

Avax Technologies Inc. (Pink:AVXT), Philadelphia, Pa.   Business: Cancer   Date completed: 12/16/09   Type: Private placement of convertible notes and warrants   Raised: $1.4 million   Investor: Firebird Management   Note: The promissory note...
07:00 , Apr 20, 2009 |  BioCentury  |  Product Development

Phase III cancer vaccines

Phase III cancer vaccines Company Product Description Indication Status Antigenics Inc. (NASDAQ:AGEN) Oncophage vitespen Heat shock protein vaccine purified from autologous tumor cells Renal cancer Ph III; approved in Russia Avax Technologies Inc. (Pink:AVXT) M-Vax...
07:00 , Apr 20, 2009 |  BioCentury  |  Finance

Cancer vaccine uplift

Cancer vaccine uplift Company 4/17 cls % wk chg Dendreon Corp. (NASDAQ:DNDN) $17.99 186% Prima Biomed Ltd. (ASX:PRR) A$0.03 100% Oxford BioMedica plc (LSE:OXB) 11.25p 72% Biovest International Inc. (Pink: BVTI) (majority-owned by Accentia Biopharmaceuticals...
08:00 , Jan 5, 2009 |  BioCentury  |  Finance

Phase III & cash constrained

Phase III & cash constrained Company 3Q08 oper loss 9/30/08 cash Years cash Lead program Active Biotech (SSE:ACTI) (A) $9.0 $28.1 0.78 Anyara in Ph III for renal cancer; laquinimod, which is partnered with Teva...
07:00 , Apr 14, 2008 |  BC Week In Review  |  Clinical News

O-Vax: Phase I/II started

Avax began a U.S. Phase I/II trial to evaluate three dose strengths of O-Vax in 42 post-surgical patients following taxane-based chemotherapy. Avax Technologies Inc. (OTCBB:AVXT), Philadelphia, Pa.   Product: O-Vax   Business: Cancer   Molecular...
07:00 , Apr 7, 2008 |  BC Week In Review  |  Company News

Avax management update

Avax Technologies Inc. (AVXT), Philadelphia, Pa.   Business: Cancer   Hired: Isabelle Fourthin as CMO for Europe, the Middle East and Africa, formerly medical director of oncology at Merck & Co. Inc. 's Paris unit...
08:00 , Jan 31, 2008 |  BC Innovations  |  Cover Story

CD200: A Solid Argument

The two companies developing anti- CD200 antibodies to treat blood cancers- Alexion Pharmaceuticals Inc. and Trillium Therapeutics Inc .-might have had a new indication land in their laps. In a paper published in The Journal...